Berezin Alexander E, Kremzer Alexander A, Samura Tatayna A
Department of Internal Medicine; Department of Clinical Pharmacology, State Medical University, Zaporozhye 69035, Ukraine.
J Biomed Res. 2015 Mar 2;30. doi: 10.7555/JBR.29.20140025.
Chronic heart failure (CHF) remains a leading cause of morbidity and mortality. In the current study, we aimed to evaluate the predictive value of circulating thrombospondin-2 (TSP-2) for cumulative survival in patients with ischemic CHF due to coronary artery disease (CAD). The results showed that during a median follow-up of 2.18 years, 21 participants died and 106 subjects were hospitalized repeatedly. The median circulating levels of TSP-2 in patients who survived and those who died were 0.63 ng/mL (95%CI=0.55-0.64 ng/mL) and 1.03 ng/mL (95% CI=0.97-1.07 ng/mL) (P<0.001). Circulating TSP-2 independently predicted all-cause mortality (OR=1.27; 95%CI=1.08-1.59; P=0.002), CHF-related death (OR=1.16; 95%CI=1.02-1.50; P<0.001), and also CHF-related rehospitalization (OR=1.12; 95%CI=1.07-1.25; P<0.001). In conclusion, among CAD patients with symptomatic CHF, increased circulating TSP-2 is correlated with increased 3-year CHF-related death, all-cause mortality, and risk for recurrent hospitalization.
慢性心力衰竭（CHF）仍然是发病和死亡的主要原因。在本研究中，我们旨在评估循环血中血小板反应蛋白-2（TSP-2）对冠状动脉疾病（CAD）所致缺血性CHF患者累积生存的预测价值。结果显示，在中位随访2.18年期间，21名参与者死亡，106名受试者反复住院。存活患者和死亡患者的TSP-2循环水平中位数分别为0.63 ng/mL（95%CI = 0.55 - 0.64 ng/mL）和1.03 ng/mL（95%CI = 0.97 - 1.07 ng/mL）（P < 0.001）。循环血中的TSP-2可独立预测全因死亡率（OR = 1.27；95%CI = 1.08 - 1.59；P = 0.002）、CHF相关死亡（OR = 1.16；95%CI = 1.02 - 1.50；P < 0.001）以及CHF相关再住院率（OR = 1.12；95%CI = 1.07 - 1.25；P < 0.001）。总之，在有症状的CAD合并CHF患者中，循环血中TSP-2升高与3年CHF相关死亡、全因死亡率增加以及再次住院风险增加相关。
